Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

924.58 -11.00 (-1.18%)
Streaming Delayed Price Updated: 11:39 AM EDT, Apr 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
This Blue-Chip Stock Is a Heavy Weight in Weight-Loss Drugs
Eli Lilly (LLY) stands out for its diversified pharmaceutical portfolio, robust pipeline, and strategic acquisitions that are fueling growth. LLY has strong technical momentum and is trading at new... 
Via Barchart.com
Topics Intellectual Property
News headline image
Eli Lilly on "Stock Split Watch": A Deep Dive into a Pharmaceutical Giant's Future
Indianapolis, IN – November 19, 2025 – Eli Lilly and Company (NYSE: LLY), the pharmaceutical titan, finds itself at the epicenter of market speculation, firmly placed on "stock split watch" as its... 
Via MarketMinute
News headline image
Eli Lilly Unusual Options Activity For November 19 ↗
 
Via Benzinga
News headline image
Stock Split Watch: Could This Unstoppable Growth Stock Be Next? ↗
Don't wait for a stock split to buy the stock, though. 
Via The Motley Fool
News headline image
Healthcare Rotation Underway: 3 Stocks Leading the Charge ↗
Via MarketBeat
News headline image
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
These stocks both have advanced in the double-digits in recent months. 
Via The Motley Fool
News headline image
2 High-Flying Stocks with Exciting Potential and 1 We Find Risky
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly... 
Via StockStory
News headline image
Why Big Pharma Won't Quit the Diet. Who Will Win the Next Weight Loss Battle? ↗
The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish line. 
Via The Motley Fool
News headline image
Can AI Drive Peloton's Comeback? ↗
The market is hopping with interesting news. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Tech Stocks Drop, Pharma Gains As Sector Rotation Picks Up: What's Moving Markets Tuesday? ↗
Wall Street endured another wave of selling in tech stocks on Tuesday, with the Nasdaq 100 down more than 1% by midday in New York, extending its month-to-date slide to more than 5%. 
Via Benzinga
News headline image
Merck Jumps On A Surprise Win; Why It Still Has A Long Road To Go ↗
Merck stock jumped Tuesday on a surprise win for its drug, sotatercept, in patients with pulmonary hypertension. 
Via Investor's Business Daily
Topics Government
News headline image
Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200% ↗
The companies are both working on oral selective estrogen receptor degraders, which break down the estrogen cancer cells need to grow. 
Via Investor's Business Daily
Topics Government
News headline image
Oprah Winfrey-Backed Wellness Stock Stumbles As GLP-1 Boom Reshapes Consumer Habits: Growth Score Plummets ↗
Prominent weight-loss and wellness company, WW International Inc. (NASDAQ: WW), backed by renowned talk show host Oprah Winfrey, has seen better days, with the company filing for bankruptcy early this... 
Via Benzinga
Topics Bankruptcy
News headline image
1 Profitable Stock with Exciting Potential and 2 Facing Challenges
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
News headline image
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q3
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Bristol-Myers Squibb (NYSE:BMY) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Branded Pharmaceuticals Stocks Q3 Earnings: Eli Lilly (NYSE:LLY) Best of the Bunch
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Eli Lilly (NYSE:LLY) and the... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Pfizer (NYSE:PFE)
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Pfizer's CEO Sends a Warning to Eli Lilly. Is the Stock a Buy? ↗
Pfizer's weight management pipeline just got a boost. 
Via The Motley Fool
News headline image
Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring ↗
AI breakthroughs in pharma are pushing Eli Lilly and healthcare stocks higher—and may soon reshape how we fight cancer. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight ↗
With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensive rotation. 
Via Benzinga
Topics ETFs
News headline image
Consumer Brands Shake Things Up...With Mergers ↗
2025 has been quite the year for consumer brands, but not in a good way. The industry has underperformed for the past three years and many of the world's largest consumer brand companies are resorting... 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Market Grapples with Valuation Fears Amidst Accelerating Sector Rotation
As November 2025 unfolds, the global financial markets find themselves at a critical juncture, characterized by a palpable sense of unease over elevated valuations in specific sectors and a pronounced... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Nvidia and 19 Other Stocks Now Make Up 50% of the S&P 500. Here's What It Means for Your Investment Portfolio. ↗
Buying the S&P 500 takes the belief that today's leading companies deserve their lofty valuations. 
Via The Motley Fool
Topics Stocks
News headline image
How Novo Nordisk Just Undercut Eli Lilly And The Trump Administration ↗
Novo Nordisk undercut Eli Lilly and the Trump administration on Monday, slashing the cash price of its Wegovy and Ozempic. 
Via Investor's Business Daily
Topics Government
News headline image
White House Economic Advisor Kevin Hassett Says India Trade Deal Talks Got ‘Pretty Complicated’, But Remains Hopeful: Report ↗
In an interview with CNBC, Hassett remained optimistic about striking an agreement with India, but added that there are a lot of different variables in the India-U.S. relationship. 
Via Stocktwits
News headline image
Novo Nordisk Offers WeGovy, Ozempic For $199 A Month As It Takes On Eli Lilly’s Zepbound ↗
The Danish drugmaker has announced that this offer is applicable to cash-paying patients looking to purchase introductory doses of Wegovy and Ozempic. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
This Sector Is Suddenly Crushing the Broader Market. Should You Invest $1,000? ↗
Healthcare stocks have far outperformed the broader market over the past month. 
Via The Motley Fool
Topics ETFs Government World Trade
News headline image
2 Mooning Stocks to Keep an Eye On and 1 We Ignore
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant... 
Via StockStory
News headline image
Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare Giants' Stocks? ↗
Investors will be watching what Trump makes happen. 
Via The Motley Fool
Topics Government
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.